Capasso Planning Partners LLC Decreases Stock Position in Eli Lilly and Company $LLY

Capasso Planning Partners LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 22.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,429 shares of the company’s stock after selling 417 shares during the quarter. Eli Lilly and Company makes up 0.6% of Capasso Planning Partners LLC’s investment portfolio, making the stock its 26th largest position. Capasso Planning Partners LLC’s holdings in Eli Lilly and Company were worth $1,114,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Rovin Capital UT ADV increased its position in shares of Eli Lilly and Company by 11.8% in the second quarter. Rovin Capital UT ADV now owns 397 shares of the company’s stock valued at $309,000 after acquiring an additional 42 shares during the period. Harvest Portfolios Group Inc. grew its stake in shares of Eli Lilly and Company by 28.3% in the second quarter. Harvest Portfolios Group Inc. now owns 161,867 shares of the company’s stock worth $126,180,000 after purchasing an additional 35,712 shares during the last quarter. Aspect Partners LLC increased its holdings in Eli Lilly and Company by 263.2% during the 2nd quarter. Aspect Partners LLC now owns 345 shares of the company’s stock valued at $269,000 after purchasing an additional 250 shares during the period. RPS Advisory Solutions LLC raised its position in Eli Lilly and Company by 13.8% during the 2nd quarter. RPS Advisory Solutions LLC now owns 1,161 shares of the company’s stock valued at $905,000 after purchasing an additional 141 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its holdings in Eli Lilly and Company by 18.3% in the 2nd quarter. Sterling Capital Management LLC now owns 51,748 shares of the company’s stock worth $40,339,000 after buying an additional 8,016 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 4,314 shares of company stock worth $2,766,929. 0.14% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on LLY shares. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Guggenheim restated a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 16th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $960.88.

Eli Lilly and Company Stock Down 1.5%

Shares of Eli Lilly and Company stock opened at $923.35 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $955.46. The firm has a market cap of $872.92 billion, a price-to-earnings ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43. The company has a 50-day moving average of $799.97 and a 200 day moving average of $775.76. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.